NCT02053636 2024-07-25
FINESSE
Servier
Phase 2 Completed
Clinical Trials
4 trialsNCT02202746 2020-06-23
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
Clovis Oncology, Inc.
Phase 2 Terminated
NCT02109016 2019-07-29
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
Clovis Oncology, Inc.
Phase 2 Terminated
NCT02747797 2018-08-02
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
University of California, San Diego
Phase 2 Withdrawn